Are current systemic endothelial anti-inflammatory therapies effective/safe, and only in secondary prophylaxis? Cover

.blurhash-client-img { display: none !important; }

Are current systemic endothelial anti-inflammatory therapies effective/safe, and only in secondary prophylaxis?

Romanian Journal of Cardiology

Volume 35 (2025): Issue 3 (September 2025)

By: Lucian Petrescu and Ciprian Rachieru

Open Access

|Sep 2025

Authors

Lucian Petrescu

petrescu_lucian@yahoo.com

1“Victor Babeș” University of Medicine and Pharmacy, Timișoara, România

Ciprian Rachieru

1“Victor Babeș” University of Medicine and Pharmacy, Timișoara, România

Municipal Emergency Clinical Hospital, Timișoara, România

Center for Advanced Research in Cardiovascular Pathology and Hemostasis, Timișoara, România

DOI: https://doi.org/10.2478/rjc-2025-0029 | Journal eISSN: 2734-6382 | Journal ISSN: 1220-658X

Journal RSS Feed

Language: English

Page range: 159 - 164

Published on: Sep 30, 2025

Published by: Romanian Society of Cardiology

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

Atherosclerosis/atherothrombosis,

“vulnerable” plaque,

residual inflammatory risk,

lipid-lowering treatments,

primary endothelial anti-inflammatory treatments,

primary non-anti-inflammatory therapies,

secondary atherothrombotic prevention studies with anti-inflammatories

Related subjects:

Clinical medicine,

Internal medicine,

Cardiac surgery,

Pediatrics and juvenile medicine,

Paediatric cardiology

© 2025 Lucian Petrescu, Ciprian Rachieru, published by Romanian Society of Cardiology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 35 (2025): Issue 3 (September 2025)Next article